Erlander Mark 4
4 · Cardiff Oncology, Inc. · Filed Mar 13, 2025
Insider Transaction Report
Form 4
Erlander Mark
DirectorChief Executive Officer
Transactions
- Award
Stock Options
2025-03-11+758,400→ 2,925,098 totalExercise: $3.58Exp: 2035-03-11→ Common Stock (758,400 underlying)
Footnotes (1)
- [F1]25% of the shares subject to the option will vest on March 11, 2026 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the continued service of the reporting person.